A case report of polyglandular syndrome induced by programmed death-1 inhibitor and literature review
10.3760/cma.j.cn311282-20200326-00218
- VernacularTitle:一例程序性死亡受体1抑制剂导致多发内分泌腺病病例报道及文献复习
- Author:
Yao WANG
;
Bao LI
;
Saichun ZHANG
;
Weijun GU
;
Yu CHENG
;
Qi NI
;
Chaohui LYU
;
Jianming BA
;
Jintao DOU
;
Yiming MU
- From:
Chinese Journal of Endocrinology and Metabolism
2021;37(5):462-466
- CountryChina
- Language:Chinese
-
Abstract:
We reported a case of polyglandular syndrome induced by programmed death-1(PD-1) inhibitors. The patient was a 51-years-old male with non-small cell lung cancer, treated with PD-1 inhibitor nivolumab/pembrolizumab because of postoperative subcarinal lymph node metastasis indicated by PET-CT. During 14 cycles of PD-1 inhibitor treatment, the patient successively developed primary hypothyroidism, and type 1 diabetes mellitus(T1DM). More than five months after the withdrawal of pembrolizumab, the patient experienced recurrentce. Laboratory examinations showed mild hyponatremia and hypopituitarism including ACTH and growth hormone(GH)/insulin-like growth factor-1(IGF-1) insufficiency. This is the first report of a patient diagnosed as polyglandular syndrome caused by PD-1 inhibitor. In particularly, the hypothyroidism and T1DM did not improve after drug withdrawal, while hypopituitarism was further aggravated. This case reminds us that we should pay more attention to the changes of endocrine function during and after the treatment of PD-1 inhibitor, so that we can make the correct diagnosis and take proper medical measures timely, to avoide missed diagnosis, and improper treatment.
